The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...